Figure 1From: Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study a: Means (± standard deviation) of plasma concentrations of zoledronic acid after 1 st infusion in Arm1 (n = 11) patients who received zoledronic acid, thalidomide and prednisolone. b: Means (± standard deviation) of plasma concentrations of zoledronic acid after 1st infusion in Arm2 (n = 12) patients who received zoledronic acid alone.Back to article page